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Mast Cells Are Required for Full Expression of
Allergen/SEB-Induced Skin Inflammation
Tomoaki Ando1, Kenji Matsumoto2, Siavash Namiranian3, Hirotaka Yamashita1, Haley Glatthorn1,
Miho Kimura1,7, Brandon R. Dolan1, James J. Lee4, Stephen J. Galli5, Yuko Kawakami1, Colin Jamora3 and
Toshiaki Kawakami1,6
Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease. We recently described an animal model in
which repeated epicutaneous applications of a house dust mite extract and Staphylococcal enterotoxin B
induced eczematous skin lesions. In this study we showed that global gene expression patterns are very similar
between human AD skin and allergen/staphylococcal enterotoxin B–induced mouse skin lesions, particularly in
the expression of genes related to epidermal growth/differentiation, skin barrier, lipid/energy metabolism,
immune response, or extracellular matrix. In this model, mast cells and T cells, but not B cells or eosinophils,
were shown to be required for the full expression of dermatitis, as revealed by reduced skin inflammation and
reduced serum IgE levels in mice lacking mast cells or T cells (TCRb / or Rag1 / ). The clinical severity of
dermatitis correlated with the numbers of mast cells, but not eosinophils. Consistent with the idea that T helper
type 2 (Th2) cells play a predominant role in allergic diseases, the receptor for the Th2-promoting cytokine thymic
stromal lymphopoietin and the high-affinity IgE receptor, FceRI, were required to attain maximal clinical scores.
Therefore, this clinically relevant model provides mechanistic insights into the pathogenic mechanism of
human AD.
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INTRODUCTION
Atopic dermatitis (AD), or eczema, is a chronic or chronically
relapsing, pruritic inflammatory skin disease. The etiology of
this disease is incompletely understood, but it is multifactorial
and the disease is manifested by complex interactions
between genetic and environmental factors (Bieber, 2008;
Boguniewicz and Leung, 2011). Pathological examination
reveals hyperkeratosis, spongiosis, and parakeratosis in
acute lesions and marked epidermal hyperplasia and
perivascular accumulation of lymphocytes and mast cells in
chronic lesions. Immunological abnormalities of AD are
characterized by sensitization with various allergens (e.g.,
foods, aeroallergens, microbes, and autoallergens), high serum
IgE levels, and skin lesions with apoptotic keratinocytes
and infiltration with immune cells such as CD4þ T cells,
eosinophils, and mast cells. These T cells express IL-4, IL-5,
and IL-13 (Grewe et al., 1998), and numerous studies suggest
an association between AD development and T helper type 2
(Th2) cell–skewed immune responses. However, there are also
data suggesting that AD development is independent of IgE,
but correlates with an increase in IFN-g-producing Th1 cells
(Tsicopoulos et al., 1994; Thepen et al., 1996; Werfel et al.,
1996). Thus, as Irvine et al. (2011) have stated, AD was
considered for many years to be primarily immunologically
driven disease with secondary barrier defect (the so-called
inside–outside hypothesis). In contrast, some investigators had
hypothesized that the primary defect is in the skin barrier (the
outside–inside hypothesis). Various loss-of-function mutations
in the FLG gene encoding filaggrin, a key protein for formation
of the skin barrier, were recently found in a substantial
proportion of AD patients (Palmer et al., 2006; Sandilands
et al., 2007) and in flaky tail mutant mice (Fallon et al., 2009).
Furthermore, tight junction proteins claudin-1 and claudin-23
are reduced in AD patients. Silencing of claudin-1, whose
expression is inversely correlated with Th2 biomarkers, in
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human keratinocytes diminishes tight junction function (De
Benedetto et al., 2011). Thus, strong association of FLG
mutations with AD and other studies have validated the
outside–inside hypothesis (Irvine et al., 2011; De Benedetto
et al., 2012). However, FLG mutations predispose subjects to
allergen sensitization but these mutations are not sufficient for
causing AD, as other genetic and environmental influences
likely promote the Th2 immune response in susceptible
individuals.
A number of mouse AD models have been developed over
the past 15 years, and have provided mechanistic insights into
the pathogenesis of human AD (Gutermuth et al., 2004; Jin
et al., 2009; Kawakami et al., 2009a). For example, a mouse
model induced by epicutaneous (EC) sensitization with
ovalbumin (OVA) mimicked skin lesions of human AD
characterized by epidermal and dermal thickening,
infiltration of CD4þ T cells and eosinophils, and local
expression of mRNAs for IL-4, IL-5, and IL-13 (Spergel et al.,
1998). Dermatitis in this model required ab T cells, but not B
cells or mast cells (Woodward et al., 2001; Alenius et al.,
2002). Different roles of IL-4, IL-5, IL-10, IL-17, IFN-g,
chemokine receptors, complement components, and
complement receptors in this model were demonstrated
using gene-manipulated mice (Jin et al., 2009). We also
developed a highly reproducible mouse model that
mimicked human AD, in which skin inflammation was
induced by repeated treatments of Dermatophagoides
farinae extract (Der f) and Staphylococcal enterotoxin B
(SEB) (Kawakami et al., 2007). Thus, AD patients often suffer
from skin infections and 490% of AD patients are colonized
with Staphylococcus aureus as compared with B5% of
healthy subjects. S. aureus infection is thought to be critical
in the pathogenesis and/or worsening of skin lesions (Strange
et al., 1996; Jappe, 2000). Moreover, there is a strong
association of human AD with house dust mite allergens
(Kimura et al., 1998; Scalabrin et al., 1999; Fuiano and
Incorvaia, 2012). In this study, we demonstrated the clinical
relevance of this model to human AD by global gene
expression analysis, and then investigated the cellular and
molecular players involved in skin inflammation in this model.
We focused particularly on the role of mast cells.
RESULTS
Gene expression profiles in lesional skin of Der f/SEB-induced
dermatitis are similar to those in human AD skin
Our previous study showed that AD-like skin lesions can be
induced by epicutaneous applications of Der f and SEB in
NC/Nga and C57BL/6 (B6) mice (Kawakami et al., 2007).
Higher clinical scores were observed with dermatitis-prone
NC/Nga mice than with B6 mice. Global gene expression
analysis of skin RNAs showed r¼ 0.956 (Spearman’s
correlation coefficient) between normal and eczematous skin
in NC/Nga mice, whereas r¼ 0.976 between normal and
eczematous skin in B6 mice. Thus, the lower values of
Spearman’s correlation coefficient might reflect higher
clinical scores in NC/Nga mice. Comparison between B6
and NC/Nga mice yielded r¼ 0.962 when healthy skin was
compared, and r¼0.970 when eczematous skin was
compared. Clustering analysis also showed higher similarity
between eczematous B6 and eczematous NC/Nga mice than
other comparisons (Supplementary Figure S1A online). These
data imply that the same pathogenic mechanisms may
underlie the development of AD-like skin lesions in both
strains of mice. In contrast, comparison between different
tissues gave lower values, e.g., r¼0.855 between normal skin
and normal spleen of B6 mice, and r¼ 0.857 between
eczematous skin and spleen of eczematous B6 mice.
To examine the clinical relevance of our Der f/SEB
induction model, we compared skin gene expression data
derived with B6 and NC/Nga mice with human AD skin
data deposited in the National Center for Biotechnology
Information (NCBI) Gene Expression Omnibus (GEO)
database. The changes in expression of genes in human AD
versus healthy skin from AD patients or healthy subjects
were compared with those of orthologous genes in mouse
eczematous versus healthy skin, using OrderedList algorithm
(Lottaz et al., 2006; Yang et al., 2006). This analysis detected
significant similarity in gene expression in the skin between
human AD and mouse AD-like dermatitis (Table 1 and
Supplementary Figure S1B online). The top genes contributing
to 95% of the similarity score were similar when our B6 and
NC/Nga results were compared with different human AD data,
and were related to epidermal growth/differentiation (e.g.,
several keratin genes, cornified cell envelope–related genes
(Sprr1b, Sprr2k, Tgm3, and Lce1m)), skin barrier function (e.g.,
several kallikrein-related peptidases and serine protease inhi-
bitors (Serpinb3d, 3a, and 13a)), immune responses (e.g.,
several cytokines, chemokines, and their receptors, S100A8,
and S100A9), lipid/energy metabolism (e.g., Slc27a2 and
Pck1), and extracellular matrix/adhesion (e.g., several matrix
metalloproteinases, their inhibitor Timp4, and Tnc). Among
these genes, Il7r, Il21r, CD8a, Ltb, Ccl5, Cxcl9, Cxcl10, Dlg2,
Zap70, Pik3r1, and Fos are involved in the development and/
or various aspects of functions of T cells, and Fcer1a, Hck,
Ccl2, Pik3r1, and Fos are involved in the development and/or
functions of mast cells (see more detail in Supplementary
Description of Microarray Data and Table S1 online).
Consistent with the altered expression of skin barrier-related
genes, Der f/SEB-induced mice had impaired skin barrier, as
revealed by high levels of transepidermal water loss
(Supplementary Figure S2 online). Expression of select genes
among the top similarity contributors was confirmed by
quantitative real-time reverse-transcriptase–PCR (Supplementary
Figure S1C online).
The above expression data, together with previous results
showing high serum IgE levels in both the majority of AD
patients and allergen-induced eczematous mice (Jin et al., 2009;
Kawakami et al., 2009a), showed high similarity between
human AD and Der f/SEB-induced skin inflammation,
supporting the clinical relevance of our model. Thus, these
results set the stage for detailed mechanistic investigations.
T cells, but not B cells, are required for maximal skin
inflammation
CD4 T cells, particularly Th2 cells, play a predominant role in
allergic diseases including AD (Boguniewicz and Leung,
T Ando et al.
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2011; Novak and Leung, 2011). To begin to analyze the
cellular requirement for allergen-induced dermatitis, we
performed the Der f/SEB experiments on T cell–deficient
TCRb / and T cell/B cell–deficient Rag1 / mice. For
comparison, B cell–deficient mMT and WT mice were also
tested. Both TCRb / and Rag1 / mice exhibited substan-
tially lower clinical scores than WT mice (Figure 1a). In
contrast, the clinical scores of mMT mice were similar to those
of WT mice. These observations were reflected in the
thicknesses of skin (Figure 1b–d). Although the epidermis
was thickened in all AD-induced mice, the dermis in TCRb /
or Rag1 / mice was not thickened after Der f/SEB treatment
(Figure 1c). The clinical scores correlated with the thicknesses
of epidermis and dermis (Figure 1d). In comparison with the
non-AD WT sample, the increased thickness of the epidermis
in AD-induced samples could be attributed to expansion of
differentiated layers, such as the stratum spinosum denoted by
keratin 1 (K1) and the stratum granulosum marked by loricrin
(Supplementary Figure S3 online). Consistent with the
perturbation of epidermal homeostasis, there was an increase
in K6 expression. Despite a defect in tight junction formation,
E-cadherin (which nucleates adherens junctions) expression
appeared normal. Consistent with our previous data (Kawakami
et al., 2007), serum IgE levels (3,076±839 ng ml1, n¼7)
were high in eczematous WT mice. In contrast, without T-cell
help, IgE levels (700±279 ng ml1, n¼6) were lower in
TCRb / mice. As expected from the lack of antibody-
producing B cells, mMT and Rag1 / mice did not have
detectable levels of serum IgE (o15.6 ng ml 1, the detection
limit, n¼8 or 6), indicating that IgE is not essential for skin
inflammation. However, this does not exclude the possibility
that IgE might contribute to some aspects of skin inflammation
(see below). These results demonstrate that T cells, but not B
cells, are required for the full expression of dermatitis in this
model, similar to the EC OVA model.
Mast cells, but not eosinophils, are required for maximal skin
inflammation
Histological analysis showed increased numbers of eosinophils
in lesional skin in TCRb / , Rag1 / , mMT, and WT mice
(Figure 2a). However, no correlation was found between the
numbers of eosinophils in skin lesions and clinical scores
observed in these mice (Figure 2b). Furthermore, the clinical
scores in Der f/SEB-treated eosinophil-deficient PHIL or
DdblGATA mice were not different from those in WT control
(Figure 2c and d), indicating that eosinophils are dispensable
for allergen-induced skin inflammation. In contrast, the
numbers of mast cells correlated positively with clinical scores
(Supplementary Figure S4 online). Clinical scores were
significantly lower in Der f/SEB-treated mast cell–deficient
KitW-sh/W-sh mice than in the corresponding WT mice
(Figure 3a). Consistent with these observations, the thicknesses
of the lesional epidermis and dermis were significantly
reduced in KitW-sh/W-sh mice (Figure 3b and c). To further
confirm the role of mast cells, KitW-sh/W-sh mice were engrafted
with bone marrow–derived mast cells generated from WT
mice. These mice exhibited clinical scores similar to WT mice
(Figure 3a). The numbers of engrafted mast cells were at
near-normal levels (1,131±98 mm2 in engrafted mice vs.
1,770±49 mm2 in WT mice). In the absence of mast cells,
Table 1. Similarity analysis of human and mouse microarray data
B6 AD-like lesional/B6
normal skin
NC/Nga AD-like lesional/NC/Nga
normal skin
GEO accession
Orthologs common
in the lists Expression fold change between Score P-value Genes Score P-value Genes
GSE6012 10,873 AD lesional/normal skin 1,198.9 o0.001 94 1,327.5 o0.001 131
GSE5667 14,325 AD lesional/normal skin 972.3 o0.001 75 976.0 o0.001 97
AD lesional/nonlesional skin 1,029.0 o0.001 61 976.6 o0.001 81
AD nonlesional/normal skin 277.8 0.845 69 366.0 0.502 65
GSE32924 14,878 AD lesional/normal skin 768.2 o0.001 56 553.7 0.014 75
AD lesional/nonlesional skin 1,283.8 o0.001 126 1,015.4 o0.001 143
AD nonlesional/normal skin 552.4 0.022 29 485.2 0.068 41
GSE16161 10,873 AD lesional/normal skin 994.1 o0.001 97 753.1 0.004 116
GSE27887 14,878 AD lesional/nonlesional skin 1,156.9 o0.001 117 910.6 o0.001 134
GSE26952 14,889 AD nonlesional/normal epidermis 888.8 o0.001 46 849.5 o0.001 50
PS nonlesional/normal epidermis 577.9 0.006 29 484.5 0.069 34
Abbreviations: AD, atopic dermatitis; GEO, Gene Expression Omnibus; PS, psoriasis.
Similarity of expression changes in human AD or PS and mouse induction models were compared using OrderedList algorithm as described in the Materials
and Methods. Human data series obtained from National Center for Biotechnology Information (NCBI) GEO are shown by GEO accession. As each data set
uses a different microarray platform, first, orthologs were matched between human and mouse data according to NCBI HomoloGene Build 65. Numbers of the
matched orthologs used in the comparisons are shown. OrderedList algorithm calculates similarity score according to the ranks of the genes listed in human
and mouse data. We used expression fold changes for ranking. When the same genes were listed in the top (upregulated) or the bottom (downregulated) end of
both human and mouse expression data, it gave a high similarity score. The similarity scores were compared with the random distribution of similarity scores
(Supplementary Figure S1B online), and P-values for the significance of similarity were obtained. Numbers of top genes that contributed to a total of 95% of the
similarity score are also shown. A full gene list is available in Supplementary Table S1 online.
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the decreased thickening of AD-induced skin was consistent
with a lower expression of K1 in AD-induced KitW-sh/W-sh mice
versus AD-induced WT mice (Figure 3d). Concerned about the
possible role of abnormalities other than the mast cell
deficiency in KitW-sh/W-sh mice (Reber et al., 2012; Rodewald
and Feyerabend, 2012), we performed Der f/SEB experiments
using the recently engineered mast cell–deficient mouse
strain Cpa3-Cre;Mcl-1fl/fl (Lilla et al., 2011). These mice
also exhibited significantly blunted skin inflammation
(Supplementary Figure S5 online). Interestingly, eosinophil
infiltration was increased in mast cell–deficient mice
(Figure 3e), whereas neutrophils were decreased (Figure 3f).
Moreover, the numbers of neutrophils were significantly
correlated with the clinical scores (Supplementary Figure S6
online). However, the role of neutrophils in our model
remains to be determined. These results strongly indicate that
mast cells are required for maximal skin inflammation.
FceRI contributes to skin inflammation
High clinical scores in mMT mice (Figure 1a) do not necessarily
indicate that immunoglobulins are not involved in AD
pathogenesis, because there are both activating and inhibitory
Fc receptors (Nimmerjahn and Ravetch, 2006) and IgE binding
to FceRI has positive effects on mast cell survival and
activation (Asai et al., 2001; Kalesnikoff et al., 2001; Kitaura
et al., 2003). Elevated IgE levels are found in up to 80% of AD
patients (Leung and Bieber, 2003), and anti-IgE therapy is
efficacious in treating severe AD patients (Vigo et al., 2006;
Amrol, 2010). Therefore, we tested whether the IgE/FceRI axis
is involved in skin inflammation. As shown in Figure 4a,
the clinical scores were significantly lower in FceRIa /
mice than in WT mice. Although hematoxylin and eosin
staining showed that epidermal/dermal thicknesses were
not altered compared with WT mice (Figure 4b and c),
immunofluorescence microscopy analysis indicated that the
increase in differentiating cell populations is slightly higher in
AD-induced FceRIa / mice compared with AD-induced
WT counterparts (Figure 4d). The same trend of expression
changes could be seen for K6 and E-cadherin. However,
consistent with the lower clinical scores, lesional skin had less
infiltration of neutrophils in FceRIa / mice (Figure 4e). One
of the major cytokines acutely secreted from FceRI-activated
mast cells is tumor necrosis factor-a (TNF-a), which is
important for late-phase allergic reactions and neutrophil
accumulation (Wershil et al., 1991). However, mice lacking
TNF-a failed to show a reduction in clinical scores (Figure 4f),
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Figure 1. T cells, but not B cells, are indispensable for maximal skin inflammation. Dermatitis induction by epicutaneous applications of Dermatophagoides
farinae extract (Der f) and Staphylococcal enterotoxin B (SEB) was performed as described in the Materials and Methods. Each symbol represents one mouse.
(a) Clinical skin scores. (b) Hematoxylin and eosin (H&E) staining of naive (upper rows) and lesional (lower rows) skin tissues. Bar¼ 200mm. (c) Thicknesses of
epidermis, dermis, and total skin (epidermisþdermis) layers, as measured in H&E-stained tissues. (d) Relationships between clinical scores and skin layer
thicknesses. Linear regression lines are shown. *Po0.05, **Po0.01, ***Po0.001, and ****Po0.0001. AD, atopic dermatitis; NS, not significant; WT, wild type.
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suggesting that factor(s) other than TNF-a may be critical for
the mast cell contribution to skin inflammation in this model
of AD.
TSLP contributes to skin inflammation
Thymic stromal lymphopoietin (TSLP) activates dendritic cells
(DCs) and TSLP-activated DCs prime naive T cells to produce
several cytokines such as IL-4, IL-5, IL-13, and TNF-a (Liu,
2006). TSLP is highly expressed by keratinocytes from AD
patients (Soumelis et al., 2002), and transgenic mice
overexpressing TSLP in keratinocytes develop AD-like
eczematous lesions (Li et al., 2005; Yoo et al., 2005). As
shown in Figure 5a, TSLP protein was highly expressed by
keratinocytes in lesional skin of B6 mice. Skin sections in
which the primary antibody was omitted suggested that the
fluorescence in hair follicles might be nonspecific. TSLP
mRNA levels were also increased in lesional skin (data not
shown). Next, we tested whether TSLP is involved in skin
inflammation in the Der f/SEB model. Importantly, mice
lacking TSLP receptor (TSLPR) exhibited substantial reduction
in clinical scores (Figure 5b). Although the thicknesses of
epidermis and dermis were not significantly different between
WT and TSLPR / mice (Figure 5c and d), the numbers of
neutrophils and eosinophils, but not mast cells, were
drastically reduced in TSLPR / mice (Figure 5e). Consistent
with the histological analysis of AD-induced samples,
expression of markers of epidermal differentiation was not
significantly different between WT and TSLPR / mice
(Figure 5f). Interestingly, K6 expression was higher in
AD-induced skin from TSLPR / mice versus WT mice.
However, serum IgE levels were not lower in TSLPR / mice
(10.1±3.8mg ml1, n¼4 vs. WT 4.4±1.1mg ml 1, n¼7).
These results collectively indicate that the TSLP/TSLPR axis is
critically involved in certain aspects of this AD model.
DISCUSSION
This and previous (Kawakami et al., 2007) studies strongly
support the clinical relevance of our Der f/SEB-induced AD
model for the following reasons. First, eczematous mice thus
induced exhibited similarity to human AD skin in gross and
microscopic morphology and pruritus. Second, eczematous
mice showed Th2 predominant skin inflammation and
elevated serum IgE levels. Third, global gene expression in
eczematous skin was similar to human AD skin, confirming
altered epidermal differentiation (leading to impaired barrier
function) and immune dysregulation in both human and
mouse diseases. Fourth, consistent with the efficacy of
anti-IgE therapy in treating severe AD patients (Belloni et al.,
2008; Liu et al., 2011), the IgE/FceRI axis was involved in Der
f/SEB-induced dermatitis. Finally, the requirement of TSLPR for
Der f/SEB-induced dermatitis was also consistent with Th2
inflammation in human AD.
To the best of our knowledge, this study represents a
previously unreported comparison in gene expression at the
genomic level between human AD and a mouse model of AD.
The genes that contribute to similarity in human AD and our
mouse model are related to epidermal growth and differentiation,
skin barrier, lipid and energy metabolism, immune response, and
extracellular matrix. Many of these genes have been implicated
in the pathophysiology of human AD (Barnes, 2010).
This study showed that mast cells and ab T cells, but not B
cells or eosinophils, are required for the full expression of
AD-like skin lesions in B6 mice. This report also demonstrates
the requirement for mast cells in an AD model (Kawakami
et al., 2009a) by using a strict set of approaches including mast
cell knock-in (Nakano et al., 1985). According to the widely
accepted notion for AD development (Bieber, 2008;
Boguniewicz and Leung, 2011), the impaired skin barrier
function allows easy access of allergens to the inside of
epidermis and dermis; allergens are taken up by Langerhans
cells and/or dermal DCs, and these cells migrate and mature
to present allergens to naive helper T cells in lymph nodes;
activated and differentiated Th2 cells migrate back to skin sites
reexposed to allergens; these effector Th2 cells recruit
eosinophils, mast cells, and other granulocytes to cause
tissue damage. Our results support this scenario, particularly
the roles of ab T cells and mast cells. The dispensability of
eosinophils shown in this study, as well as the dispensability of
CCR3 (the chemokine receptor essential for eosinophil
recruitment) in another AD model (Ma et al., 2002),
probably indicates that tissue-damaging functions of
eosinophils are redundant with those of other cells. Despite
the apparent involvement of the IgE/FceRI axis in certain
features of Der f/SEB-induced dermatitis, including clinical
score and numbers of neutrophils, B cells were not required
for the full expression of the dermatitis. This could be
interpreted as reflecting a balance between positive and
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negative regulatory functions of immunoglobulins in allergic
inflammation. IgG receptors such as FcgRI, FcgRIIIA, and
FcgRIV are activating receptors, whereas FcgRIIB is an
inhibitory receptor (Nimmerjahn and Ravetch, 2006).
FcgRIIB inhibits FceRI-mediated activation as well (Kraft and
Novak, 2006). The cellular requirements for dermatitis
development in our model were not identical to those of the
EC OVA model, as dermatitis in the latter model required ab T
cells, but not B or mast cells (Woodward et al., 2001; Alenius
et al., 2002). In contrast, skin inflammation induced by EC
sensitization with cedar pollen antigens was abolished in
mast cell–deficient mice (Oiwa et al., 2008). The mast cell
contribution to dermatitis development in that model and our
model, but not in the EC OVA model, might be due to the use
of complex allergens containing component(s) that trigger
mast cell activation. Similar to our model, FceRI was shown
to be involved in dermatitis in an EC OVA sensitization model
(Abboud et al., 2009). Although reduced natural killer cell
activity was shown in our model and it led to severe erosive
skin lesions upon vaccinia virus infection (Kawakami et al.,
2009b), the natural killer cell activity seemed normal in the EC
OVA model. Therefore, the two AD models might mimic
different aspects of the AD phenotype. Alternatively, these
different models reflect heterogeneity of human AD.
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Several studies have implicated TNF-a as an important
factor in skin inflammation: TNF-a expression is high in AD
and psoriatic lesional skin (Zimmermann et al., 2011); TNF-a
and IFN-g induce keratinocyte apoptosis (Konur et al., 2005);
TNF-a inhibits barrier protein expression (filaggrin and
loricrin) via a c-Jun N-terminal kinase–dependent pathway
(Kim et al., 2011); and TNF-a and TWEAK (TNF-like weak
inducer of apoptosis) cooperate in the induction of apoptosis
in primary keratinocytes and artificial skin equivalents.
TWEAK upregulates TNF-a expression in keratinocytes. High
TWEAK expression was observed in AD lesions, but not in
healthy skin or psoriatic lesions (Zimmermann et al., 2011).
Although TNF-a could be produced by T cells and mast cells,
the two cell types required for the full expression of dermatitis,
TNF-a was not required for Der f/SEB-induced dermatitis. As
anti-TNF-a therapy is effective in treating psoriasis (Kircik and
Del Rosso, 2009; Langley et al., 2010), but not AD (Pua and
Barnetson, 2006; Belloni et al., 2008), this result also supports
the relevance of our Der f/SEB-induced dermatitis as a model
of human AD.
TSLP is considered a master regulator of allergic inflammation
(Liu, 2006). TSLP activates DCs and TSLP-activated DCs prime
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naive T cells to produce Th2 cytokines (IL-4, IL-5, and IL-13)
and TNF-a. TSLPR is expressed on other immune cells as well,
and TSLP is necessary and sufficient for allergic inflammation
(Ziegler and Artis, 2010). Given that TSLP is highly expressed
by keratinocytes from AD patients (Soumelis et al., 2002),
and Der f/SEB-induced dermatitis and transgenic mice
overexpressing TSLP in keratinocytes develop AD-like
eczematous lesions (Li et al., 2005; Yoo et al., 2005), it was
not surprising that TSLPR was required for Der f/SEB-induced
dermatitis. Considering the requirement of T cells in maximal
Der f/SEB-induced dermatitis and the dispensability of
T cells for dermatitis in keratinocyte-specific TSLP transgenic
mice, it is tempting to speculate that T cells are required
for the expression of TSLP in keratinocytes and they
become dispensable after high-level expression of TSLP is
attained. In this context, mast cells, which express TSLPR
(Allakhverdi et al., 2007), might exert an effector role
downstream of TSLP. Alternatively, mast cells, together with
T cells, might also be required for TSLP production in
keratinocytes, as mast cells stimulated via FceRI produce
TSLP (Soumelis et al., 2002; Okayama et al., 2009) and
combinations of Th2 cytokines and inflammatory cytokines
(IL-1a or TNF-a) can induce TSLP production in keratinocytes
(Bogiatzi et al., 2007).
In summary, this study has strengthened the clinical
relevance of Der f/SEB-induced model of AD. By establishing
its cellular and molecular basis, this model should be a
useful tool for further studying the pathogenesis of AD and
developing novel therapeutic strategies to the treatment of
human AD.
MATERIALS AND METHODS
Der f/SEB-induced dermatitis
Dermatitis was induced in NC/Nga, C57BL/6 (B6) mice, or mutant
mice with a C57BL/6 genetic background as previously described
(Kawakami et al., 2007). NC/Nga mice were purchased from Charles
River Japan (Yokohama, Japan) (www.crj.co.jp). mMT (Kitamura et al.,
1991), TCRb / (Mombaerts et al., 1991), Rag1 / (Mombaerts
et al., 1992), KitW-sh/W-sh (Grimbaldeston et al., 2005), Cpa3-Cre;Mcl-
1fl/fl (Lilla et al., 2011), PHIL (Lee et al., 2004), DdblGATA (Yu et al.,
2002), FceRIa / (Dombrowicz et al., 1993), TNF-a / (Pasparakis
et al., 1996), TSLPR / (Al-Shami et al., 2004), and GM-CSF /
(Stanley et al., 1994) mice have been previously described. Briefly,
solutions of 500 ng of SEB (Sigma-Aldrich, St Louis, MO) and 10mg of
Der f extract (100mg ml 1, Greer Laboratories, Lenoir, NC) were
pipetted on a 1 cm 1 cm square gauze pad placed on the shaved
area. This portion of the back skin was occluded with a Tegaderm
Transparent Dressing (3M HealthCare, St Paul, MN) using bandages.
After 3 days, the dressings were replaced with a new one. After an
additional 4 days had passed, the dressings were removed and the
mice were kept without treatment for the next week. The 1-week Der
f/SEB treatment was repeated once more. Clinical severity was scored
by an investigator who did not know the identities of mice 2 days
after removing the dressings in the last cycle. Clinical scores were
based on the severity (0, no symptoms; 1, mild; 2, intermediate; and
3, severe) of four possible symptoms (redness, bleeding, eruption, and
scaling). Der f/SEB experiments were performed using 3–6 mice per
group and cumulative data from 2 to 5 experiments are presented.
Animal experiments were approved by the Animal Care and Use
Committee of the La Jolla Institute for Allergy and Immunology.
Other experimental procedures, together with detailed description
of microarray data, and Supplementary Table and Figures, can be
found in the Supplementary Data online.
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